Use of Samples. Approved samples not destroyed in testing will be sent to the Owner’s Representative at the Project. Approved samples of hardware in good condition will be marked for identification and may be used in the Work. Materials and equipment incorporated in the Work must match the approved samples. Samples not destroyed in testing and not approved will be returned at the Private Entity’s expense if the Private Entity so requests in writing at the time of submission.
Use of Samples. Gateway reserves the right to use samples of goods provided under this purchase order for future quoting requirements for any third party.
Use of Samples. Impax shall procure, either itself or through CSO, that the Sales Force shall:
(a) only use samples of the Shire Product for sampling purposes directly in connection with the provision of the Services; and
(b) not resell, repackage, modify, deconstruct, reverse engineer or otherwise use samples of the Shire Product or its packaging in any other manner.
Use of Samples. Omeros shall transfer to Affitech the sufficient or requested quantities of proteins, reagents and/or other materials involved in the Services as specified in the Initial Research Plan and any Additional Research Plan(s) (“Omeros Samples”). Omeros shall provide all pertinent information known to Omeros regarding the Omeros Samples to the extent necessary for carrying out the Initial Research Plan and any Additional Research Plan(s). Affitech shall be responsible for [†]. Affitech shall not use or analyze any Omeros Samples provided by Omeros under this Agreement except as necessary to carry out the Initial Research Plan or any Additional Research Plan(s) and shall not administer [†]. After completion of the Services, Affitech shall either return the Omeros Samples to Omeros or dispose of the Omeros Samples, upon written request by Omeros and at Omeros’ risk and expense. Affitech [†] of all Omeros Samples or other compounds or materials used in the performance of the Services and shall [†] of the Omeros Samples after delivery to Affitech.
Use of Samples. Omeros shall transfer to North Coast the sufficient or requested quantities of proteins, reagents, antibodies and/or other materials involved in the Services as specified in any Research Plan (“Samples”). Omeros shall provide all pertinent information known to Omeros regarding the Samples to the extent necessary for carrying out any Research Plan. North Coast shall be responsible for and bear the expense of obtaining any other chemicals, materials, equipment, animals and facilities needed to conduct the Services and produce the Deliverables. North Coast shall not use or analyze any Samples provided under this Agreement except as necessary to carry out the relevant Research Plan and shall not administer or permit the Samples to be administered to any person. After completion of the Services, North Coast shall either return the Samples to Omeros or dispose of the Samples, upon written request by Omeros and at Omeros’ risk and expense. North Coast accepts full responsibility for safe handling of all Samples or other compounds or materials used in the performance of the Services and shall be responsible for any loss or destruction of the Samples after delivery to North Coast.
Use of Samples. (a) Each party will be responsible for accountability and compliance with the PDMA, and other applicable federal, state, and local laws and regulations relating to such samples or the distribution of same. Inyx and King each will be responsible for adherence by its respective sales representatives to such laws and regulations. Each party or its appointed agents will have the right to audit the records and/or reports for the Products samples, as required to be kept by the other party under the PDMA, pursuant to the provisions of Article 10 of the Collaboration Agreement.
Use of Samples. 3.1 Parties must use Samples only for purposes that are consistent with the consent obtained and in compliance with relevant laws and regulations.
3.2 Additional individual donor consent and ethics committee/IRB approval must be obtained when the research use intended is inconsistent with or beyond the scope of the original consent.
3.3 Additional consent should also be obtained if the original consent did not include analysis of DNA (if relevant to the research proposal) or use of any associated medical information (if relevant to the research proposal).
3.4 In circumstances where individual re-consent cannot practicably be obtained, approval of an ethics committee or IRB (if permissible under the relevant laws and regulation) must be sought to determine whether the research can proceed in the absence of individual consent. PROJECTS INVOLVING CLINICAL TRIALS For Projects involving the performance of clinical trials, the Collaboration Agreement shall include provisions as appropriate which normally appear in a Third Party clinical trial agreement, including without limitation: Which Party(s) will be the sponsor of the clinical trial; Obligation on the sponsor(s) to ensure that the clinical trial is conducted in accordance with all applicable laws and regulations, [the Declaration of Helsinki, and ICH GCP]; Obligation on the sponsor to ensure that regulatory and ethics committee approvals and patient informed consents have been obtained before the clinical trial commences; Which Party(s) is responsible for preparing and reviewing the protocol; Which Party(s) will make the study drug available; Auditing rights and access to records of “essential documents” for the Party making the study drug available; Reporting requirements re adverse events and an annual safety report; Which Party(s) is responsible for reporting adverse events to regulatory authorities; Detailed allocation of responsibilities for drug supply (including recall); Detailed allocation of responsibilities for the clinical study – e.g. site selection, preparation of investigator’s brochure, negotiation and execution of clinical trial agreements; Obligation on the sponsor to comply with the requirements of [the European Union legislation on Good Manufacturing Practices for Investigational Medicinal Products to the extent that the Institution performs the activities described in Annex 13 of the Good Manufacture Practice, Volume 4, “Manufacture of Investigational Medicinal Products”]; Right of Part...
Use of Samples. During the Copromotion Period the Product samples supplied by King to Wyeth or to King’s sales representatives shall be used by Wyeth and King solely in making Detail calls to Physicians in the Territory pursuant to this Agreement. Upon its receipt of Product samples, Wyeth shall be responsible for accountability and compliance with the PDMA, and other applicable federal, state and local laws and regulations relating to such samples or the distribution of same. King shall be responsible for accountability and compliance with the PDMA, and other applicable federal, state and local laws and regulations relating to Product samples that King supplies for distribution by King’s sales representatives. Wyeth and King each shall be responsible for adherence by its respective sales representatives to such laws and regulations. Each Party or its appointed agents shall have the right to audit the records and/or reports for the Product samples, as required to be kept by the other Party under the PDMA, during normal business hours, at convenient times and upon no less than [***] prior notice, provided, however, that no such audit shall occur more than [***] after the end of the Copromotion Period. Pursuant to Section 11 of the Transition Plan, after the Copromotion Period Wyeth shall at King’s option and expense either return or destroy all of the Product samples in Wyeth’s, its Affiliates’ or its employees’ control.
Use of Samples. It is permissible for USC Healthcare Professionals to utilize drug samples in the treatment of their patients, so long as the samples are not resold, billed for or used for an individual healthcare professional’s personal benefit, and are distributed in accordance with this policy. However, USC Healthcare Professionals should never allow the provision of free drug samples to influence their clinical decision-making or purchasing decisions.
Use of Samples. Product samples supplied by KING to AHPC or to KING's sales representatives shall be used by AHPC and KING solely in making Detail calls to Physicians in the Territory pursuant to this Agreement. Upon its receipt of Product samples, AHPC shall be responsible for accountability and compliance with the PDMA, and other applicable federal, state and local laws and regulations relating to such samples or the distribution of same. KING shall be responsible for accountability and compliance with the PDMA, and other applicable federal, state and local laws and regulations relating to Product samples that KING supplies for distribution by KING's sales representatives. AHPC and KING each shall be responsible for adherence by its respective sales representatives to such laws and regulations. Each party or its appointed agents shall have the right to audit the records and/or reports for the Product samples, as required to be kept by the other party under the PDMA, during normal business hours, at convenient times and upon no less than five (5) calendar days' prior notice.
